title: Euro heart failure survey. Medical treatment not in line with current guidelines.
abstract: It was the aim of the Euro Heart Survey on Heart Failure to assess whether patients are being treated according to current guidelines.
  
  
  METHODS
  In Germany, patients were screened in 7 medical centers if their discharge diagnoses were myocardial infarction, a new episode of atrial fibrillation, or diabetes mellitus. Patients were enrolled if at least one additional criterion was fulfilled: (1) clinical diagnosis of heart failure, (2) hospital admission due to heart failure within the last 3 years, (3) therapy with loop diuretic, (4) medication for heart failure or ventricular dysfunction documented by echocardiography within the past 24 hours prior to death.
  
  
  RESULTS
  2166 patients were screened of whom 747 were included in the study (478 men, 269 women). 93% of the patients suffered from heart failure. Despite the high number of patients with known heart failure (ischemic heart failure in 71%), only 72% received ACE inhibitors and 62% beta-blockers. Average daily dose met recommendations in only 63% of patients on ACE inhibitors and 54% on beta-blockers. 74% of the patients received diuretics (furosemide 36%, thiazide 34%, spironolactone 17%).
  
  
  CONCLUSIONS
  An inadequately low number of patients with heart failure receives medical therapy according to guidelines, despite all the overwhelming evidence for improved morbidity and mortality. Awareness of physicians needs to be improved.
authors.affiliation: Universität Leipzig-Herzzentrum, Leipzig, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Drechsler
authors.forename: R
authors.initials: R
authors.lastname: Dietz
authors.forename: H
authors.initials: H
authors.lastname: Klein
authors.forename: K C
authors.initials: KC
authors.lastname: Wollert
authors.forename: D
authors.initials: D
authors.lastname: Storp
authors.forename: J
authors.initials: J
authors.lastname: Molling
authors.forename: U
authors.initials: U
authors.lastname: Zeymer
authors.forename: J
authors.initials: J
authors.lastname: Niebauer
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000367:Age Factors; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005060:Europe; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D019983:Guideline Adherence; D006306:Health Surveys; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D010359:Patient Readmission; D017410:Practice Guidelines as Topic; D012737:Sex Factors; D049994:Sodium Potassium Chloride Symporter Inhibitors / Q000627:therapeutic use; D013223:Statistics as Topic; D016019:Survival Analysis; D018487:Ventricular Dysfunction, Left / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D004232:Diuretics; D005343:Fibrinolytic Agents; D049994:Sodium Potassium Chloride Symporter Inhibitors